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Background
HIV-associated facial lipoatrophy (HAFL) is known to
produce disturbances on quality of life (QOL) and emo-
tional status in people living with HIV. Reparatory treat-
ment with facial infiltrations has been proposed as a safe
and effective strategy [1], although long-term psychologi-
cal benefits remain unknown [2].
Methods
We assessed the satisfaction (SAT) and QOL in a group of
145 patients who received facial infiltrations with Aqua-
mid® to repair their HAFL at least 3 years before. SAT was
evaluated by self-reported visual-analogue scales (adapted
to: non-satisfied; mildly satisfied; satisfied; very satisfied),
and QOL by the assessment of the perceived limitation in
the following areas: work, family, social and sexual part-
ner (Likert scales: 0: no limitation; 1: low; 2: moderate; 3:
high). Adherence to antiretroviral treatment was also eval-
uated (0–100%). Frequencies, cross-tables and t-tests
were performed.
Summary of results
Baseline demographic and clinical data were as follow:
mean age: 47.2 (± 7.04) years; gender: 82.8% men; mean
years since HIV diagnosis: 15.8 (± 4.1); mean years since
first antiretroviral treatment: 9.2 (± 4.9). Severe HAFL was
present in 61.8% of participants. Long-term data were col-
lected at a mean time of 4.18 (± 0.35) years after infiltra-
tions. The most common adverse events included nodules
(14.6%) and indurations (6.3%). Only one patient pre-
sented a local infection in the infiltrated area. The major-
ity of participants (88.9%) were satisfied or very satisfied
with the results of the intervention; in patients with
adverse events, this was reported in the 80.5% of subjects.
With respect to limitations in different QOL areas, means
of scores decreased significantly in most patients com-
pared with rates before the intervention: work: 1.66 vs.
0.86 (p < 0.001); family: 2.05 vs. 0.67 (p < 0.001); social:
1.38 vs. 1.05 (p = 0.116); sexual partner: 1.88 vs. 0.69 (p
< 0.001). Levels of adherence were substantially high:
100% in 94.4% of the total sample; a similar percentage
was seen in the group of patients reporting adverse events:
100% in 97.6% subjects.
Conclusion
Long-term psychological benefits may be reached with
facial reconstruction in HIV-infected people with HAFL.
High levels of SAT and a good QOL were observed at least
4 years after the intervention.
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